Adar Poonawalla sets aside Rs 10 cr to support students travelling abroad

By: |
August 05, 2021 12:54 PM

"Dear students travelling abroad, as a few countries are yet to approve Covishield as an acceptable vaccine for travel without quarantine, you may have to incur some costs. I have set aside Rs 10 crore for this...," Poonawalla said in a tweet.

Adar Poonawalla"Dear students travelling abroad, as a few countries are yet to approve Covishield as an acceptable vaccine for travel without quarantine, you may have to incur some costs. I have set aside Rs 10 crore for this...," Poonawalla said in a tweet.

Serum Institute of India CEO and owner Adar Poonawalla on Thursday said that he has set aside Rs 10 crore to support students travelling abroad for studies, as a few countries are yet to approve Covishield as an acceptable vaccine for entry without quarantine.

“Dear students travelling abroad, as a few countries are yet to approve Covishield as an acceptable vaccine for travel without quarantine, you may have to incur some costs. I have set aside Rs 10 crore for this…,” Poonawalla said in a tweet. He also shared a link for students to apply for financial support, if needed. Earlier in July, he had lauded 16 European countries for recognising Covishield as an acceptable vaccine for entry.

“It is indeed good news for travellers, as we see sixteen European countries recognising Covishield as an acceptable vaccine for entry. However, despite being vaccinated, entry guidelines might vary from country to country, so do read up before you travel,” Poonawalla had said in a tweet.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19 vaccination drive: Two-thirds of adult population vaccinated with first dose
2Novavax, SII apply to WHO for emergency use listing of COVID vaccine
3Not many places left for COVID-19 virus to evade immunity: UK vaccine creator